3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
235
Lung Neoplasms
106
Ovarian Neoplasms
81
Breast Neoplasms
81
Fallopian Tube Neoplasms
51
Small Cell Lung Carcinoma
42
Neoplasms
41
Triple Negative Breast Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
31
Head and Neck Neoplasms
25
Adenocarcinoma of Lung
25
Parkinson Disease 4, Autosomal Dominant Lewy Body
24
Carcinoma
23
Neoplasm Metastasis
20
Carcinoma, Ovarian Epithelial
18
Melanoma
14
Lymphoma, Large B-Cell, Diffuse
14
Carcinoma, Squamous Cell
14
Brain Neoplasms
14
Prostatic Neoplasms
13
Recurrence
12
Lymphoma
12
Endometrial Neoplasms
12
Adenocarcinoma, Bronchiolo-Alveolar
12
Esophageal Neoplasms
11
Lymphoma, Non-Hodgkin
10
Hodgkin Disease
10
Brenner Tumor
10
Urinary Bladder Neoplasms
9
Central Nervous System Neoplasms
9
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Non Small Cell Lung Cancer NSCLC
×
Carboplatin
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA